June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Efficacy of dexamethasone intravitreal implant in diabetic macular edema
Author Affiliations & Notes
  • Sophie BONNIN
    Ophthalmology, Hôpital Lariboisière, Université Paris Diderot - Sorbonne Paris Cité, APHP, Paris, France
  • Benedicte Dupas
    Ophthalmology, Hôpital Lariboisière, Université Paris Diderot - Sorbonne Paris Cité, APHP, Paris, France
  • Julien Perol
    Ophthalmology, Hôpital Lariboisière, Université Paris Diderot - Sorbonne Paris Cité, APHP, Paris, France
  • Ali Erginay
    Ophthalmology, Hôpital Lariboisière, Université Paris Diderot - Sorbonne Paris Cité, APHP, Paris, France
  • Ramin Tadayoni
    Ophthalmology, Hôpital Lariboisière, Université Paris Diderot - Sorbonne Paris Cité, APHP, Paris, France
  • Pascale Massin
    Ophthalmology, Hôpital Lariboisière, Université Paris Diderot - Sorbonne Paris Cité, APHP, Paris, France
  • Footnotes
    Commercial Relationships Sophie BONNIN, None; Benedicte Dupas, Novartis (C); Julien Perol, None; Ali Erginay, Novartis (R), Bayer (R), Alimera (C); Ramin Tadayoni, Alcon (C), Novartis (C), Allergan (C), DORC (R), Bausch + Lomb (R), FCI-Zeiss (C), Takeda (R), Alimera (R), Bayer (C); Pascale Massin, Novartis (C), Allergan (C), Fovea Pharmaceutical (C), Fournier Abbott (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 2383. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Sophie BONNIN, Benedicte Dupas, Julien Perol, Ali Erginay, Ramin Tadayoni, Pascale Massin; Efficacy of dexamethasone intravitreal implant in diabetic macular edema. Invest. Ophthalmol. Vis. Sci. 2013;54(15):2383.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To report the results of intravitreal dexamethasone implant (Dex-I) injection in the treatment of diabetic macular edema (DME).

Methods: Retrospective, interventional case series. Eyes that received Dex-I for decreased visual acuity as the result of persistent DME were included in a retrospective chart review. The main outcome measures were visual acuity (VA) and central macular thickness (CMT) at 2 and 4 months after injection. Secondary outcome measures included changes in intra-ocular pressure (IOP) and analysis of therapeutic response in sub-groups.

Results: 38 eyes of 33 consecutive diabetic patients were included (mean age : 62 years). The mean duration of DME was 28 months (range 6-60). Twenty eight patients (33 eyes) had received previous treatments for DME (intravitreal injection of anti-vascular endothelial growth factor, steroids or laser photocoagulation), including 11 eyes with previous vitrectomy. Five eyes were treatment-naïve. All eyes showed a significant decrease of CMT with median change of -223 µm (-57 à -468 µm) at 2 months ; between 2 and 4 months, macular thickness increased significantly in 76% of cases, overcoming baseline thickness in 24% of eyes and concomittent of a loss of vision in 36% of cases. The median VA gain was 5 ETDRS letters [-15 to 21] at 2 months and 3 letters [-11 to 27] at 4 months. A gain of more than 10 letters was observed in 27 % of cases at 2 months and 24% at 4 months. Eight eyes (21%) developed a transient IOP increase 2 months after injection, which was successfully managed with medical treatment.

Conclusions: At 2 months, I-Dex treatment allowed systematic anatomic improvement in all patients, and fonctional improvement in more than half cases, with good safety. However, recurrence of edema was observed in 76% of cases at 4 months, leading to re-treatment in more than one third of cases.

Keywords: 499 diabetic retinopathy • 585 macula/fovea • 505 edema  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×